PMID- 37096803
OWN - NLM
STAT- MEDLINE
DCOM- 20230810
LR  - 20230810
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 129
IP  - 17
DP  - 2023 Sep 1
TI  - Increased plasma levels of monocyte chemoattractant protein-1 in patients with 
      hepatitis B virus pre-S2 gene deletion mutation predict a higher risk of 
      hepatocellular carcinoma recurrence after curative surgical resection.
PG  - 2621-2636
LID - 10.1002/cncr.34815 [doi]
AB  - BACKGROUND: Despite resection surgery as a curative therapy for hepatocellular 
      carcinoma (HCC), the high rate of postoperative HCC recurrence remains a big 
      challenge for patient survival. Chronic hepatitis B virus (HBV) infection is the 
      most important risk factor for HCC. Deletion mutation in the HBV pre-S2 gene 
      leads to expression of an essential viral oncoprotein called pre-S2 mutant and 
      represents an independent prognostic biomarker for HCC recurrence after curative 
      surgical resection. Additionally, cytokines are multifunctional secreted proteins 
      and implicated in all stages of HBV-related HCC tumorigenesis. METHODS: This 
      study aimed to identify the cytokines whose plasma levels were associated with 
      pre-S2 gene deletion mutation and HCC recurrence and evaluate their potential to 
      be combined with pre-S2 gene deletion mutation in predicting HCC recurrence. 
      RESULTS: Among a panel of 27 cytokines examined, plasma levels of monocyte 
      chemoattractant protein-1 (MCP-1) were significantly upregulated in patients with 
      pre-S2 gene deletion mutation or HCC recurrence. MCP-1 was validated as an 
      independent prognostic biomarker for HCC recurrence. Moreover, patients with both 
      the presence of pre-S2 gene deletion mutation and high levels of MCP-1 displayed 
      a higher risk of HCC recurrence than patients with either one or none of these 
      two biomarkers. The combination of pre-S2 gene deletion mutation and MCP-1 levels 
      exhibited a better prognostic performance for HCC recurrence than each biomarker 
      alone. CONCLUSIONS: This study discovered that MCP-1 levels had a significance to 
      be as a combination biomarker with pre-S2 gene deletion mutation providing an 
      improved performance in predicting HCC recurrence after curative surgical 
      resection.
CI  - (c) 2023 American Cancer Society.
FAU - Jeng, Long-Bin
AU  - Jeng LB
AUID- ORCID: 0000-0002-4588-2268
AD  - Organ Transplantation Center, China Medical University Hospital, Taichung, 
      Taiwan.
AD  - Department of Surgery, China Medical University Hospital, Taichung, Taiwan.
AD  - Cell Therapy Center, China Medical University Hospital, Taichung, Taiwan.
FAU - Li, Tsai-Chung
AU  - Li TC
AD  - Department of Public Health, College of Public Health, China Medical University, 
      Taichung, Taiwan.
AD  - Department of Healthcare Administration, College of Medical and Health Science, 
      Asia University, Taichung, Taiwan.
FAU - Wang, John
AU  - Wang J
AD  - Department of Pathology, China Medical University Hospital, Taichung, Taiwan.
FAU - Teng, Chiao-Fang
AU  - Teng CF
AUID- ORCID: 0000-0002-5218-0571
AD  - Organ Transplantation Center, China Medical University Hospital, Taichung, 
      Taiwan.
AD  - Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 
      Taiwan.
AD  - Program for Cancer Biology and Drug Development, China Medical University, 
      Taichung, Taiwan.
AD  - Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230425
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (CCL2 protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/genetics/surgery
MH  - Chemokine CCL2/genetics/metabolism
MH  - Gene Deletion
MH  - *Hepatitis B
MH  - Hepatitis B Surface Antigens/genetics/metabolism
MH  - Hepatitis B virus/genetics
MH  - *Hepatitis B, Chronic/complications/genetics/pathology
MH  - *Liver Neoplasms/genetics/surgery/pathology
MH  - Mutation
OTO - NOTNLM
OT  - hepatitis B virus
OT  - hepatocellular carcinoma
OT  - monocyte chemoattractant protein-1
OT  - pre-S2 gene deletion mutation
OT  - recurrence
EDAT- 2023/04/25 17:43
MHDA- 2023/08/10 06:42
CRDT- 2023/04/25 07:03
PHST- 2023/03/29 00:00 [revised]
PHST- 2022/12/28 00:00 [received]
PHST- 2023/04/04 00:00 [accepted]
PHST- 2023/08/10 06:42 [medline]
PHST- 2023/04/25 17:43 [pubmed]
PHST- 2023/04/25 07:03 [entrez]
AID - 10.1002/cncr.34815 [doi]
PST - ppublish
SO  - Cancer. 2023 Sep 1;129(17):2621-2636. doi: 10.1002/cncr.34815. Epub 2023 Apr 25.